The brain is extremely complicated three dimensional structures made up of interconnected neurons and neuroglia cells. It entails all type of functions of our body whether we are healthy or in disease conditions. Brain is accountable for our connectivity with the surroundings; all this is performed by an organized and systemic electrical activity of neurons by which they communicate messages to and from the brain. The abnormal electrical activity leading to the intense outburst of impulses, results in the development of epilepsy. Epilepsy is typified by recurrent, unprovoked seizures as a result excessive, hypersynchronous discharge of neurons occurs in the brain. Nearly 1% of the population throughout the worldwide is suffering from epilepsy and almost 75% begins at childhood. The patients almost one third are resistant to current available antiepileptic drugs. We don’t have the deep knowledge of the pathophysiology of the disease which can prove useful in further research for drugs with new mechanisms of action for diseases. This paper covers the role various neurotransmitters and neuropeptides in the pathophysiology of epilepsy. Our objective is to introduce the scientists with that aspect of the disease which may prove useful for further development of new drugs of epilepsy to overcome the resistance shown by the patientsorithm.
14 October 2025 in Epilepsy and paroxysmal conditions
Bioelectronic medicine is a field of study that is constantly evolving as a result of recent advancements and improvements in bioelectronic technology, which have led to novel approaches and perspectives in disease diagnosis and therapy, particularly in the inflammatory reflex immuno-regulatory functioning and, vagus nerve stimulation (VNS). The vagus nerve, an elongated nerve in the autonomic nervous system, controls a number of physiological processes in humans, including blood pressure, breathing rate, vasomotor activity, and certain reflex movements. Recent bioelectronic research has led to clinical tests using VNS for inflammatory diseases and other conditions. By sending steady, gentle electric impulses through the vagus nerve to the brain, bioelectronic devices can activate the vagus nerve. The integration of artificial intelligence (AI) with bioelectronic medicine is transforming drug development processes. AI technology can accelerate or even eliminate many time-consuming tasks, allowing healthcare professionals to use their time more efficiently and ultimately improving healthcare outcomes. This review discusses the vagus nerve’s roles in inflammation, stimulation, and regulation in animal models, as well as its therapeutic potential in treating human inflammation. Additionally, it examines how AI-powered bioelectronic drugs are being explored for conditions such as paralysis and immune disorders, and addresses the challenges of delivering large molecules using these drugs. The article emphasizes current trends, advancements, and the promising future applications of combining AI with bioelectronic medicine.
25 April 2026 in Epilepsy and paroxysmal conditions
A substantial amount of progress has been made in the field of neurohumoral transmission, which has led to the disclosure of precise details regarding the communication mechanisms that occur within the neurological system. This review article gives an extensive analysis of neurohumoral transmission, focusing on the evolving concept of co-transmission and its implications for understanding psychiatric disorders in adolescents. It first provides details on classical neurotransmitters: acetylcholine, serotonin, dopamine, glutamate, and gamma-aminobutyric acid and their role in neuronal communication. Recent research findings have shown that many neurons have the ability to simultaneously release one or more than one neurotransmitter, a phenomenon termed as co-transmission and seem to add complexity to how signals are processed through the nervous system. This phenomenon raises important implications in adolescent psychiatric disorders such as depression, anxiety, schizophrenia, attention deficit hyperactivity disorder, and autism spectrum disorder, which inevitably worsen during this stage of critical development. Recent findings suggest that diminished neurotransmitter co-transmission in certain regions, such as the prefrontal cortex, might be associated with some of these impaired cognitive and emotional regulatory processes. Understanding these complex mechanisms might provide insights into the development of effective treatments targeting several neurotransmitter systems simultaneously-especially during adolescence, when the brain is particularly sensitive to chemical interactions. This review integrates recent findings into a discussion on their implications for treatment strategies, and it hints at new pharmacological interventions directed at modulating co-transmission pathways that can enhance mental health outcomes in adolescents.